Table 4 Liver function-related parameters and serum lipids before and 12 weeks after consuming FRVE among women
Group (total = 42) | |||||||
|---|---|---|---|---|---|---|---|
Control (n = 20) | FRVE (n = 22) | ||||||
0 weeks | 12 weeks | pa | 0 weeks | 12 weeks | pa | pb | |
AST (IU/L)* | 20.00 (± 1.66) | 18.70 (± 1.02) | 0.581 | 18.86 (± 1.03) | 18.77 (±1.10) | 0.776 | |
△ change | −1.30 (± 1.60) | −0.09 (±0.64) | 0.699 | ||||
ALT (IU/L)* | 15.68 (± 2.83) | 14.89 (± 1.61) | 0.669 | 13.82 (± 1.29) | 14.18 (±1.41) | 0.798 | |
△ change | −0.79 (± 2.34) | 0.36 (±1.28) | 0.818 | ||||
AST/ALT ratio | 1.55 (± 0.11) | 1.45 (± 0.12) | 0.119 | 1.52 (± 0.10) | 1.46 (±0.09) | 0.646 | |
△ change | −0.10 (± 0.06) | −0.05 (±0.11) | 0.235 | ||||
GGT (mg/dL)* | 17.80 (± 2.42) | 16.70 (± 2.42) | 0.023 | 18.55 (± 2.59) | 17.59 (±3.01) | 0.112 | |
△ change | −1.10 (± 0.64) | −0.95 (±0.93) | 0.136 | ||||
ALP | 66.55 (± 3.42) | 64.85 (± 2.95) | 0.320 | 66.45 (± 5.11) | 66.05 (±5.21) | 0.755 | |
△ change | −1.70 (± 1.67) | −0.41 (±1.30) | 0.805 | ||||
TC (mg/dL) | 190.00 (± 5.64) | 186.10 (± 5.46) | 0.180 | 180.05 (± 6.60) | 178.18 (±6.45) | 0.618 | |
△ change | −3.90 (± 2.80) | −1.86 (±3.68) | 0.667 | ||||
TG (mg/dL)* | 119.15 (± 24.23) | 93.75 (± 12.64) | 0.054 | 107.68 (± 18.88) | 103.05 (±19.43) | 0.421 | |
△ change | −25.40 (± 12.56) | −4.64 (±9.17) | 0.203 | ||||
HDL-C (mg/dL) | 62.80 (± 3.36) | 63.85 (± 2.76) | 0.494 | 66.91 (± 3.51) | 65.91 (±3.52) | 0.525 | |
△ change | 1.05 (± 1.51) | −1.00 (±1.55) | 0.769 | ||||
LDL-C (mg/dL) | 103.37 (± 4.77) | 103.50 (± 5.50) | 0.968 | 95.63 (± 6.42) | 96.40 (±6.43) | 0.831 | |
△ change | 0.13 (± 3.24) | 0.77 (±3.56) | 0.276 | ||||